Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies
Figure 1
Clinical significance of NM23-H1 expression in hematologic malignancies. (a) Overexpression of NM23-H1 gene in hematologic malignancies [10, 20, 31]. Quantitative RT-PCR analysis on NM23-H1 mRNA in human bone marrow mononuclear cells (BM-MNC) in normal (), AML (), acute lymphoblastic leukemia (ALL, ), and chronic myelogenous leukemia in the chronic phase (CML-CP, ), CML in blast crisis (CML-BC, ), myelodysplastic syndrome (MDS, ), MDS overt leukemia (). The mRNA levels were normalized for gapdh mRNA. The positive control (the index = 100) is represented by RNA extracted from the human leukemia cell line (HEL). Mann-Whitney’s U test (versus normal), *, **. (b) Overall survival curves of patients with AML, according to NM23-H1 expression level [31]. High NM23-H1 (>100 index) patients (, solid line) had a worse prognosis than low NM23-H1 (≤100) patients (, broken line).
